242 related articles for article (PubMed ID: 20371952)
1. Plasma renin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, azelnidipine, in hypertensive patients.
Kondo T; Goto R; Sonoda K; Yasuda T; Ono K; Takaki Y; Yatsuda R; Miyamura N; Araki E
Intern Med; 2010; 49(7):637-43. PubMed ID: 20371952
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension.
Inomata J; Murai H; Kaneko S; Hamaoka T; Ikeda T; Kobayashi D; Usui S; Furusho H; Sugiyama Y; Takata S; Takamura M
J Hypertens; 2014 Sep; 32(9):1898-904. PubMed ID: 24979307
[TBL] [Abstract][Full Text] [Related]
3. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function--a crossover trial (AGENT).
Fukao K; Shimada K; Hiki M; Kiyanagi T; Hirose K; Kume A; Ohsaka H; Matsumori R; Kurata T; Miyazaki T; Daida H
Cardiovasc Diabetol; 2011 Sep; 10():79. PubMed ID: 21906391
[TBL] [Abstract][Full Text] [Related]
4. Azelnidipine is a useful medication for the treatment of heart failure preserved ejection fraction.
Kiuchi S; Hisatake S; Kabuki T; Oka T; Dobashi S; Fujii T; Ikeda T
Clin Exp Hypertens; 2017; 39(4):350-354. PubMed ID: 28513286
[TBL] [Abstract][Full Text] [Related]
5. Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity.
Nagasu H; Satoh M; Fujimoto S; Tomita N; Sasaki T; Kashihara N
Hypertens Res; 2012 Mar; 35(3):348-55. PubMed ID: 22072106
[TBL] [Abstract][Full Text] [Related]
6. On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone.
Konoshita T; Kaeriyama S; Urabe M; Nakaya T; Yamada M; Ichikawa M; Yamamoto K; Sato S; Imagawa M; Fujii M; Makino Y; Zenimaru Y; Wakahara S; Suzuki J; Ishizuka T; Nakamura H;
Biosci Rep; 2016 Oct; 36(5):. PubMed ID: 27515419
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of azelnidipine tablets on morning hypertension.
Kario K; Sato Y; Shirayama M; Takahashi M; Shiosakai K; Hiramatsu K; Komiya M; Shimada K
Drugs R D; 2013 Mar; 13(1):63-73. PubMed ID: 23512719
[TBL] [Abstract][Full Text] [Related]
8. A new Ca-antagonist, azelnidipine, reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension: a randomized, double-blind, placebo-controlled trial.
Arita M; Hashizume T; Tanigawa K; Yamamoto H; Nishio I
J Cardiovasc Pharmacol; 1999 Feb; 33(2):186-92. PubMed ID: 10028925
[TBL] [Abstract][Full Text] [Related]
9. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Inoue T; Node K
Am J Med Sci; 2007 Jun; 333(6):321-6. PubMed ID: 17570983
[TBL] [Abstract][Full Text] [Related]
10. Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure.
Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Fukuda T; Numao T; Shimada K; Kario K
J Cardiovasc Pharmacol; 2007 Jun; 49(6):394-400. PubMed ID: 17577104
[TBL] [Abstract][Full Text] [Related]
11. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological profiles and clinical effects of azelnidipine, a long-acting calcium channel blocker].
Sada T; Saito H
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):539-47. PubMed ID: 14639008
[TBL] [Abstract][Full Text] [Related]
13. Effects of the T/L-type calcium channel blocker benidipine on albuminuria and plasma aldosterone concentration. A pilot study involving switching from L-type calcium channel blockers to benidipine.
Tani S; Takahashi A; Nagao K; Hirayama A
Int Heart J; 2014; 55(6):519-25. PubMed ID: 25310932
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
Ishimitsu T; Numabe A; Masuda T; Akabane T; Okamura A; Minami J; Matsuoka H
Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
[TBL] [Abstract][Full Text] [Related]
15. Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.
Kimura Y; Kitagawa K; Oku N; Kajimoto K; Kato H; Tanaka M; Sakaguchi M; Hougaku H; Sakoda S; Hatazawa J
Hypertens Res; 2008 Dec; 31(12):2147-54. PubMed ID: 19139604
[TBL] [Abstract][Full Text] [Related]
16. Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure.
Ohmura C; Watada H; Shimizu T; Sakai K; Uchino H; Fujitani Y; Kanazawa A; Hirose T; Kawamori R
Endocr J; 2007 Dec; 54(5):805-11. PubMed ID: 17895576
[TBL] [Abstract][Full Text] [Related]
17. Effects of azelnidipine on uric acid metabolism in patients with essential hypertension.
Miyazaki S; Hamada T; Hirata S; Ohtahara A; Mizuta E; Yamamoto Y; Kuwabara M; Nosaka Y; Igawa O; Ogino K; Kato M; Yoshida A; Ninomiya H; Cheng J; Moriwaki Y; Yamamoto K; Hisatome I
Clin Exp Hypertens; 2014; 36(7):447-53. PubMed ID: 24433018
[TBL] [Abstract][Full Text] [Related]
18. β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension.
Browne GA; Griffin TP; O'Shea PM; Dennedy MC
Clin Endocrinol (Oxf); 2016 Mar; 84(3):325-31. PubMed ID: 26300226
[TBL] [Abstract][Full Text] [Related]
19. Plasma renin activity and aldosterone concentrations in hypertensive cats with and without azotemia and in response to treatment with amlodipine besylate.
Jepson RE; Syme HM; Elliott J
J Vet Intern Med; 2014; 28(1):144-53. PubMed ID: 24428319
[TBL] [Abstract][Full Text] [Related]
20. Comparison between screening for primary aldosteronism with and without drug adjustment.
Hua Y; He Q
Blood Press; 2024 May; 33(1):2350981. PubMed ID: 38824645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
